Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BGT226
- Development stage
- Phase 2
- Lead developer
- Novartis
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
BGT226 (also known as NVP-BGT226 or BGT-226) is an orally bioavailable, small molecule dual inhibitor of phosphatidylinositol 3-kinase (PI3K) and mammalian target of rapamycin (mTOR). It acts as a potent pan-class I PI3K inhibitor with preference for the alpha isoform and inhibits both mTORC1 and mTORC2 complexes. By blocking the PI3K/AKT/mTOR signaling pathway, it suppresses cell growth, induces G0/G1 cell cycle arrest, promotes autophagy, and may trigger apoptotic cell death in cancer cells. Developed by Novartis for the treatment of solid tumors including advanced breast cancer and pancreatic cancer, its maximum clinical trial phase reached was Phase II before development was discontinued[1][2][6][7][8].
- Other names
- BGT226 maleateBGT-226 maleateBGT 226 maleateBGT-226 free baseBGT226 free baseBGT 226 free base
02
Targets
PIK3CB (Phosphatidylinositol 3-kinase beta subunit)PIK3C3 (PI3K class III)PIK3CD (Phosphatidylinositol 3-kinase delta)PIK3CG (Phosphatidylinositol 4,5-bisphosphate 3-kinase gamma)PIK3CA (Phosphoinositide 3-kinase alpha)mTOR (Mammalian target of rapamycin kinase)
Beyond the preview
Go deeper on BGT226.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BGT226.